Handelen Bolt Biotherapeutics, Inc. - BOLT CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.0244 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024068% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.001846% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Belangrijkste statistieken
| Prev. Close* | 1.3078 |
| Open* | 1.2978 |
| 1-Jaarlijkse Verandering* | -55.09% |
| Dagelijks bereik* | 1.2978 - 1.3277 |
| 52 wekelijks bereik | 1.18-3.14 |
| Weekgemiddelde volume (10 dagen) | 180.81K |
| Gemiddeld volume (3 maanden) | 5.82M |
| Marktkapitalisatie | 49.34M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 37.66M |
| Omzet | 4.83M |
| EPS | -2.55 |
| Dividend (opbrengst %) | N/A |
| Beta | -100.00K |
| Volgende inkomsten datum | N/A |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Mar 24, 2023 | 1.3178 | 0.0200 | 1.54% | 1.2978 | 1.3377 | 1.2978 |
| Mar 23, 2023 | 1.3078 | -0.0598 | -4.37% | 1.3676 | 1.4076 | 1.3078 |
| Mar 22, 2023 | 1.4076 | -0.0599 | -4.08% | 1.4675 | 1.4675 | 1.3776 |
| Mar 21, 2023 | 1.4475 | 0.0499 | 3.57% | 1.3976 | 1.4975 | 1.3776 |
| Mar 20, 2023 | 1.4176 | 0.0200 | 1.43% | 1.3976 | 1.4376 | 1.3676 |
| Mar 17, 2023 | 1.4176 | -0.0499 | -3.40% | 1.4675 | 1.4875 | 1.3976 |
| Mar 16, 2023 | 1.4975 | 0.0699 | 4.90% | 1.4276 | 1.5174 | 1.4176 |
| Mar 15, 2023 | 1.4675 | 0.0699 | 5.00% | 1.3976 | 1.4975 | 1.3976 |
| Mar 14, 2023 | 1.5075 | 0.1099 | 7.86% | 1.3976 | 1.5075 | 1.3976 |
| Mar 13, 2023 | 1.3976 | 0.1098 | 8.53% | 1.2878 | 1.4076 | 1.2678 |
| Mar 10, 2023 | 1.2678 | -0.1198 | -8.63% | 1.3876 | 1.3877 | 1.2678 |
| Mar 9, 2023 | 1.3876 | -0.1298 | -8.55% | 1.5174 | 1.5674 | 1.3677 |
| Mar 8, 2023 | 1.5773 | -0.0200 | -1.25% | 1.5973 | 1.5973 | 1.5274 |
| Mar 7, 2023 | 1.6073 | 0.0599 | 3.87% | 1.5474 | 1.6273 | 1.5474 |
| Mar 6, 2023 | 1.5674 | -0.0898 | -5.42% | 1.6572 | 1.6672 | 1.5174 |
| Mar 3, 2023 | 1.6373 | 0.0200 | 1.24% | 1.6173 | 1.7071 | 1.6173 |
| Mar 2, 2023 | 1.6173 | 0.0400 | 2.54% | 1.5773 | 1.6672 | 1.5773 |
| Mar 1, 2023 | 1.6472 | 0.1298 | 8.55% | 1.5174 | 1.6772 | 1.5174 |
| Feb 28, 2023 | 1.5973 | 0.0799 | 5.27% | 1.5174 | 1.6173 | 1.5174 |
| Feb 27, 2023 | 1.5873 | 0.0499 | 3.25% | 1.5374 | 1.6173 | 1.4874 |
Bolt Biotherapeutics, Inc. Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| No events scheduled | ||
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Totale inkomsten | 1.26 | 0.231 | 0.215 | 0 |
| Inkomsten | 1.26 | 0.231 | 0.215 | 0 |
| Totale bedrijfskosten | 94.048 | 49.413 | 31.184 | 11.629 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 18.393 | 9.056 | 5.182 | 2.209 |
| Onderzoek & Ontwikkeling | 75.655 | 40.357 | 26.002 | 9.42 |
| Bedrijfsresultaat | -92.788 | -49.182 | -30.969 | -11.629 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.281 | 0.199 | 0.524 | 0.193 |
| Overige, Netto | -6.084 | -11.745 | -0.042 | -0.153 |
| Netto inkomen voor belastingen | -98.591 | -60.728 | -30.487 | -11.589 |
| Netto inkomen na belastingen | -98.591 | -60.728 | -30.487 | -11.589 |
| Netto inkomen voor extra. Posten | -98.591 | -60.728 | -30.487 | -11.589 |
| Netto inkomen | -98.591 | -60.728 | -30.487 | -11.589 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -98.591 | -60.728 | -30.487 | -11.589 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -98.591 | -60.728 | -30.487 | -11.589 |
| Verwaterd Netto Inkomen | -98.591 | -60.728 | -30.487 | -11.589 |
| Verwaterd Gewogen Gemiddelde Aandelen | 33.1967 | 36.3279 | 34.5218 | 34.5218 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -2.9699 | -1.67166 | -0.88312 | -0.3357 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| Verwaterde Genormaliseerde Winst per Aandeel | -2.9699 | -1.67166 | -0.88312 | -0.3357 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0.813 | 0.508 | 0.752 | 0 | 0 |
| Inkomsten | 0.813 | 0.508 | 0.752 | 0 | 0 |
| Totale bedrijfskosten | 24.689 | 27.583 | 24.278 | 23.761 | 18.426 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 6.304 | 5.099 | 4.941 | 4.054 | 4.299 |
| Onderzoek & Ontwikkeling | 18.385 | 22.484 | 19.337 | 19.707 | 14.127 |
| Bedrijfsresultaat | -23.876 | -27.075 | -23.526 | -23.761 | -18.426 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.198 | -0.082 | 0.131 | 0.176 | 0.056 |
| Overige, Netto | 0 | 0 | 0 | 0 | -6.084 |
| Netto inkomen voor belastingen | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Netto inkomen na belastingen | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Netto inkomen voor extra. Posten | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Netto inkomen | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Verwaterd Netto Inkomen | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Verwaterd Gewogen Gemiddelde Aandelen | 37.1279 | 37.3143 | 37.2068 | 36.5951 | 21.4983 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.63774 | -0.72779 | -0.62878 | -0.64448 | -1.13748 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.63774 | -0.72779 | -0.62878 | -0.64448 | -1.13748 |
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Totaal vlottende activa | 189.16 | 25.361 | 35.9 | 14.1 |
| Geldmiddelen en kortetermijnbeleggingen | 186.219 | 22.838 | 34.826 | 13.634 |
| Geldmiddelen & Equivalenten | 27.383 | 5.542 | 34.826 | 13.634 |
| Korte Termijn Investeringen | 158.836 | 17.296 | 0 | 0 |
| Prepaid Expenses | 2.941 | 2.523 | 1.074 | 0.466 |
| Total Assets | 307.718 | 46.542 | 48.447 | 15.975 |
| Property/Plant/Equipment, Total - Net | 30.603 | 16.384 | 11.517 | 1.442 |
| Property/Plant/Equipment, Total - Gross | 32.848 | 17.623 | 12.162 | 1.856 |
| Accumulated Depreciation, Total | -2.245 | -1.239 | -0.645 | -0.414 |
| Other Long Term Assets, Total | 2.607 | 4.797 | 1.03 | 0.433 |
| Total Current Liabilities | 21.328 | 11.264 | 8.656 | 2.755 |
| Accounts Payable | 3.574 | 1.598 | 2.095 | 0.892 |
| Accrued Expenses | 14.885 | 8.164 | 5.962 | 1.823 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.04 | ||
| Other Current Liabilities, Total | 2.869 | 1.502 | 0.599 | 0 |
| Total Liabilities | 57.599 | 46.193 | 16.788 | 3.551 |
| Total Long Term Debt | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 36.271 | 34.929 | 8.132 | 0.796 |
| Total Equity | 250.119 | 0.349 | 31.659 | 12.424 |
| Preferred Stock - Non Redeemable, Net | 105.296 | 77.505 | 28.367 | |
| Common Stock | 0.00037 | 0.00036 | 0 | 0 |
| Additional Paid-In Capital | 457.43 | 3.452 | 1.825 | 1.241 |
| Retained Earnings (Accumulated Deficit) | -206.99 | -108.399 | -47.671 | -17.184 |
| Other Equity, Total | -0.32137 | -0.00036 | 0 | 0 |
| Total Liabilities & Shareholders’ Equity | 307.718 | 46.542 | 48.447 | 15.975 |
| Total Common Shares Outstanding | 37.3997 | 36.3279 | 34.5218 | 34.5218 |
| Long Term Investments | 85.348 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 196.088 | 189.16 | 222.488 | 248.151 | 271.21 |
| Geldmiddelen en kortetermijnbeleggingen | 190.901 | 186.219 | 212.893 | 244.988 | 266.669 |
| Geldmiddelen & Equivalenten | 44.021 | 27.383 | 23.649 | 58.302 | 95.481 |
| Korte Termijn Investeringen | 146.88 | 158.836 | 189.244 | 186.686 | 171.188 |
| Prepaid Expenses | 5.187 | 2.941 | 9.595 | 3.163 | 4.541 |
| Total Assets | 282.793 | 307.718 | 333.55 | 347.074 | 324.637 |
| Property/Plant/Equipment, Total - Net | 29.911 | 30.603 | 30.868 | 30.553 | 15.418 |
| Property/Plant/Equipment, Total - Gross | 32.518 | 32.848 | 32.926 | 32.311 | 16.925 |
| Accumulated Depreciation, Total | -2.607 | -2.245 | -2.058 | -1.758 | -1.507 |
| Long Term Investments | 54.313 | 85.348 | 77.639 | 65.938 | 36.236 |
| Other Long Term Assets, Total | 2.481 | 2.607 | 2.555 | 2.432 | 1.773 |
| Total Current Liabilities | 19.306 | 21.328 | 23.695 | 19.25 | 12.012 |
| Accounts Payable | 4.446 | 3.574 | 5.155 | 1.614 | 2.888 |
| Accrued Expenses | 11.412 | 14.885 | 13.333 | 13.306 | 7.622 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 3.448 | 2.869 | 5.207 | 4.33 | 1.502 |
| Total Liabilities | 54.399 | 57.599 | 58.637 | 51.178 | 21.389 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 35.093 | 36.271 | 34.942 | 31.928 | 9.377 |
| Total Equity | 228.394 | 250.119 | 274.913 | 295.896 | 303.248 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
| Common Stock | 0.00037 | 0.00037 | 0.00037 | 0.00037 | 0.00036 |
| Additional Paid-In Capital | 460.458 | 457.43 | 454.784 | 452.357 | 436.165 |
| Retained Earnings (Accumulated Deficit) | -230.668 | -206.99 | -179.833 | -156.438 | -132.853 |
| Other Equity, Total | -1.39637 | -0.32137 | -0.03837 | -0.02337 | -0.06436 |
| Total Liabilities & Shareholders’ Equity | 282.793 | 307.718 | 333.55 | 347.074 | 324.637 |
| Total Common Shares Outstanding | 37.4713 | 37.3997 | 37.2481 | 37.191 | 36.3318 |
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -98.591 | -60.728 | -30.487 | -11.589 |
| Geldmiddelen uit Operationele Activiteiten | -57.066 | -47.308 | -26.343 | -9.872 |
| Geldmiddelen uit Operationele Activiteiten | 1.193 | 0.611 | 0.335 | 0.302 |
| Niet-Geldelijke Posten | 19.825 | 15.092 | 1.544 | 0.276 |
| Contant Betaalde Rente | 0 | 0.004 | ||
| Veranderingen in het Operationeel Kapitaal | 20.507 | -2.283 | 2.265 | 1.139 |
| Geldmiddelen uit Investeringsactiviteiten | -232.201 | -20.592 | -0.508 | -0.29 |
| Kapitaaluitgaven | -2.338 | -3.262 | -0.508 | -0.29 |
| Overige Cash Flow investeringsposten, Totaal | -229.863 | -17.33 | 0 | 0 |
| Geldmiddelen uit Financieringsactiviteiten | 311.108 | 39.597 | 48.627 | 19.094 |
| Financiering van Cash Flow Posten | 0 | 39.303 | 48.595 | 19.113 |
| Uitgifte (Aflossing) van aandelen, netto | 311.108 | 0.294 | 0.072 | 0.02 |
| Uitgifte (Aflossing) van Schulden, Netto | 0 | -0.04 | -0.039 | |
| Nettowijziging in Geldmiddelen | 21.841 | -28.303 | 21.776 | 8.932 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -23.678 | -98.591 | -71.434 | -48.039 | -24.454 |
| Cash From Operating Activities | -24.314 | -57.066 | -39.272 | -20.545 | -16.559 |
| Cash From Operating Activities | 0.357 | 1.193 | 0.832 | 0.528 | 0.272 |
| Non-Cash Items | 4.556 | 19.825 | 16.21 | 12.401 | 8.994 |
| Changes in Working Capital | -5.549 | 20.507 | 15.12 | 14.565 | -1.371 |
| Cash From Investing Activities | 40.845 | -232.201 | -253.234 | -237.123 | -190.521 |
| Capital Expenditures | -0.605 | -2.338 | -1.776 | -0.761 | -0.058 |
| Other Investing Cash Flow Items, Total | 41.45 | -229.863 | -251.458 | -236.362 | -190.463 |
| Cash From Financing Activities | 0.107 | 311.108 | 310.613 | 310.428 | 297.019 |
| Issuance (Retirement) of Stock, Net | 0.107 | 311.108 | 310.613 | 310.428 | 297.019 |
| Net Change in Cash | 16.638 | 21.841 | 18.107 | 52.76 | 89.939 |
| Financing Cash Flow Items | 0 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| Vivo Capital, LLC | Venture Capital | 10.2793 | 3871291 | 0 | 2022-12-31 | MED |
| Sofinnova Investments, Inc | Venture Capital | 7.3138 | 2754437 | 0 | 2022-12-31 | MED |
| Citadel Advisors LLC | Hedge Fund | 7.3077 | 2752162 | 114 | 2022-12-31 | HIGH |
| Pivotal Bioventure Partners Investment Advisor LLC | Investment Advisor | 5.0224 | 1891467 | 0 | 2022-12-31 | LOW |
| Engleman Edgar G | Individual Investor | 3.2402 | 1220280 | -57947 | 2022-03-01 | |
| Nan Fung Group Holdings Ltd | Corporation | 3.0986 | 1166952 | 0 | 2022-12-31 | LOW |
| Newtyn Management, LLC | Hedge Fund | 3.0536 | 1150000 | 550000 | 2022-12-31 | MED |
| Samsara BioCapital, LLC | Venture Capital | 2.7858 | 1049153 | 0 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.4648 | 928276 | -11993 | 2022-12-31 | LOW |
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 2.0474 | 771059 | 0 | 2022-12-31 | LOW |
| Stanford Management Company | Endowment Fund | 1.9106 | 719546 | 0 | 2022-12-31 | MED |
| Renaissance Technologies LLC | Hedge Fund | 1.1724 | 441539 | 47681 | 2022-12-31 | HIGH |
| Hawkeye Capital Management, LLC | Hedge Fund | 1.102 | 415039 | 0 | 2022-12-31 | MED |
| Tang Capital Management, LLC | Hedge Fund | 1.0621 | 400000 | 200000 | 2022-12-31 | MED |
| Goldman Sachs & Company, Inc. | Research Firm | 0.7515 | 283028 | 270883 | 2022-12-31 | MED |
| Oasis Management Company Ltd. | Investment Advisor/Hedge Fund | 0.7435 | 280000 | 0 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.7131 | 268547 | -153412 | 2022-12-31 | LOW |
| Millennium Management LLC | Hedge Fund | 0.6463 | 243401 | 125022 | 2022-12-31 | HIGH |
| Assenagon Asset Management S.A. | Investment Advisor | 0.5996 | 225816 | -54165 | 2022-12-31 | HIGH |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.4981 | 187600 | 74400 | 2022-12-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group500K+
Handelaren
92K+
Actieve klanten per maand
$53M+
Maandelijks beleggingsvolume
$30M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Bolt Biotherapeutics, Inc. Company profile
Over Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc is een immuno-oncologisch bedrijf in een klinische fase. Het bedrijf ontwikkelt tumorgerichte therapieën die gebruik maken van de kracht van het aangeboren en het adaptieve immuunsysteem. Haar immuunstimulerende antilichaamconjugaatbenadering (ISAC) maakt gebruik van immuunstimulantia om myeloïde cellen, waaronder macrofagen en dendritische cellen, aan te spreken en te activeren, die tumorcellen doden via fagocytose en tumorneoantigenen blootstellen aan het adaptieve immuunsysteem. De productkandidaat van de Vennootschap, BDC-1001, is een humane epidermale groeifactor receptor 2 (HER2) Boltbody ISAC bestaande uit een HER2-targeting biosimilar, van trastuzumab geconjugeerd met één van de TLR7/8 agonisten, voor de behandeling van patiënten met HER2-expresserende solide tumoren, inclusief die met HER2-arme tumoren. De TLR's (Toll-like receptors) activeren myeloïde cellen en maken de presentatie van tumorgeassocieerde neoantigenen aan cytotoxische T-cellen mogelijk.
| Industry: | Bio Therapeutic Drugs |
900 Chesapeake Drive
REDWOOD CITY
CALIFORNIA 94063
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen